KR20240095326A - 심혈관 상태를 치료하는 방법 및 심장 대사의 효율을 증가시키는 방법 - Google Patents

심혈관 상태를 치료하는 방법 및 심장 대사의 효율을 증가시키는 방법 Download PDF

Info

Publication number
KR20240095326A
KR20240095326A KR1020247018009A KR20247018009A KR20240095326A KR 20240095326 A KR20240095326 A KR 20240095326A KR 1020247018009 A KR1020247018009 A KR 1020247018009A KR 20247018009 A KR20247018009 A KR 20247018009A KR 20240095326 A KR20240095326 A KR 20240095326A
Authority
KR
South Korea
Prior art keywords
dose
imb
subjects
trimetazidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018009A
Other languages
English (en)
Korean (ko)
Inventor
자이크리슈나 파텔
폴 체임벌린
Original Assignee
임브리아 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임브리아 파마슈티칼스, 인크. filed Critical 임브리아 파마슈티칼스, 인크.
Publication of KR20240095326A publication Critical patent/KR20240095326A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020247018009A 2021-11-01 2022-10-31 심혈관 상태를 치료하는 방법 및 심장 대사의 효율을 증가시키는 방법 Pending KR20240095326A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274389P 2021-11-01 2021-11-01
US63/274,389 2021-11-01
PCT/US2022/048401 WO2023076665A1 (en) 2021-11-01 2022-10-31 Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism

Publications (1)

Publication Number Publication Date
KR20240095326A true KR20240095326A (ko) 2024-06-25

Family

ID=86158627

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018009A Pending KR20240095326A (ko) 2021-11-01 2022-10-31 심혈관 상태를 치료하는 방법 및 심장 대사의 효율을 증가시키는 방법

Country Status (9)

Country Link
US (1) US20250235447A1 (https=)
EP (1) EP4426301A4 (https=)
JP (1) JP2024540172A (https=)
KR (1) KR20240095326A (https=)
CN (1) CN118647381A (https=)
AU (1) AU2022376557A1 (https=)
CA (1) CA3236328A1 (https=)
IL (1) IL312523A (https=)
WO (1) WO2023076665A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054580A1 (en) * 2023-09-08 2025-03-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
TWI683808B (zh) * 2017-07-18 2020-02-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有胺或(硫)醯胺之lxr調節劑
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation

Also Published As

Publication number Publication date
US20250235447A1 (en) 2025-07-24
WO2023076665A1 (en) 2023-05-04
EP4426301A1 (en) 2024-09-11
JP2024540172A (ja) 2024-10-31
AU2022376557A1 (en) 2024-05-02
CN118647381A (zh) 2024-09-13
CA3236328A1 (en) 2023-05-04
IL312523A (en) 2024-07-01
EP4426301A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
Watkins et al. Diabetes and its management
Chapman et al. Cilostazol: a review of its use in intermittent claudication
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
WO2014005013A2 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
Karamat et al. The acute effect of beta‐guanidinopropionic acid versus creatine or placebo in healthy men (ABC‐Trial): a randomized controlled first‐in‐human trial
Ghosh et al. Churchill's Pocketbook of Diabetes E-Book
KR20240095326A (ko) 심혈관 상태를 치료하는 방법 및 심장 대사의 효율을 증가시키는 방법
Mayadunne et al. Long‐term effects of metformin on offspring health: A review of current evidence and future directions
Baranowski et al. Effect of exogenous β-hydroxybutyrate on BDNF signaling, cognition, and amyloid precursor protein processing in humans with T2D and insulin-resistant rodents
KR20230028535A (ko) 트리메타지딘의 변형 형태의 변형 방출 제제
US20210401833A1 (en) Modified release formulations of modified forms of trimetazidine
CA2304899C (en) New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease
US20210401834A1 (en) Modified release formulations of modified forms of trimetazidine
Tablets et al. PrJAMP Pioglitazone
Agent Pr PRO-PIOGLITAZONE
Tablets et al. Pr ACT PIOGLITAZONE
Agent PrRAN™-PIOGLITAZONE
Agent Pr AURO-PIOGLITAZONE
Standard et al. PrACCEL PIOGLITAZONE
Baranowski et al. Effect of exogenous β-hydroxybutyrate on BDNF signalling, cognition, and amyloid 1 precursor protein processing in humans with T2D and insulin resistant rodents 2 3 4
Agent KOMBOGLYZE®
Nutraceuticals Selected Abstracts from the National Congress of the Italian Society for Cardiovascular Prevention (SIPREC), Naples, Italy, 8–10 March 2012
Agent PrVAN-Pioglitazone
Hydrochloride et al. PrMYLAN-PIOGLITAZONE

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000